Paul Wesley Noble

US Patent:

20140050740, Feb 20, 2014

Filed:

Apr 12, 2012

Appl. No.:

14/111338

Inventors:

Paul W. Noble - Chapel Hill NC, US
Dianhua Jiang - Chapel Hill NC, US

Assignee:

DUKE UNIVERSITY - Durham NC

International Classification:

A61K 39/395
A61K 31/7088

US Classification:

4241581, 514 44 A, 435 74, 4241721

Abstract:

Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease.

US Patent:

20190099471, Apr 4, 2019

Filed:

Oct 3, 2018

Appl. No.:

16/150379

Inventors:

- Los Angeles CA, US
Dianhua Jiang - Encino CA, US
Paul W. Noble - Beverly Hills CA, US

International Classification:

A61K 38/20
A61K 31/728
A61P 11/00
A61K 45/06

Abstract:

The described invention provides a method of treating a lung injury at risk of progressing to a fibrotic lung disease in a subject in need thereof comprising administering to the subject a composition comprising a therapeutic amount of IL-6 polypeptide, hyaluronan (HA), mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof, wherein the therapeutic amount is effective to increase renewal of alveolar epithelial cell 2 (AEC2) stem cells, to repair the injury, to reduce lung fibrosis, or a combination thereof.

US Patent:

20150258192, Sep 17, 2015

Filed:

Mar 12, 2015

Appl. No.:

14/656492

Inventors:

Colleen Brophy - Nashville TN, US
Cynthia Lander - Mendham NJ, US
Paul W. Noble - Beverly Hills CA, US

International Classification:

A61K 39/395
A61K 38/08
A61K 9/00
A61K 38/17

Abstract:

The described invention provides compositions and methods for reducing lung allograft dysfunction after lung transplant and for treating a severe pulmonary fibrosis characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The methods comprise administering to a subject in need thereof a composition comprising an antibody component comprising a therapeutic amount of an anti-CD44 antibody; and an MK2 inhibitor component comprising a therapeutic amount of an MK2 inhibitor (MK2i) polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or at least one peptide functionally equivalent to the therapeutic domain thereof selected from a polypeptide of amino acid sequence KALARQLAVA (SEQ ID NO: 8), a polypeptide of amino acid sequence KALARQLGVA (SEQ ID NO: 9) and a polypeptide of aminoacid sequence KALARQLGVAA (SEQ ID NO: 2), or a functional equivalent thereof, and a pharmaceutically acceptable carrier.